Bharat Book Bureau

Bharatbook added a new report on “Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets” into its market report catalogue for reselling.

Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets

The study offers an overview of the Multiple Sclerosis disease-modifying product market, including regulatory issues, and accompanied by detailed analyses and forecasts by product. MS is an autoimmune disease characterized by the body’s own immune system attacking itself and causing spots of demyelination (plaques) in the brain and spinal cord. Symptoms of MS vary widely depending on the severity of the disease and which nerve cells are attacked. Today there are currently eight disease-modifying therapies for MS approved throughout the world. Biologics represent the largest class of MS disease-modifying therapies by sales and by number of approved therapies accounting for six out of the eight approved MS disease-modifying products (Avonex, Betaseron, CinnoVex, Extavia, Rebif, and Tysabri). Of these biologics, five are beta interferon products. All of these approved MS agents are able to slow down the progression of the disease but none can reverse any nerve damage that occurs due to demyelination. ( http://www.bharatbook.com/detail.asp?id=152283&rt=Multiple-Sclerosis-MSDrugs-and-Biologics-Technologies-and-Global-Markets.html )

For each drug or biologic for MS on the market, all agents for MS in mid-to-late stages of clinical development, and some in earlier stages of development we have examined where these compounds stand in the development process, the major challenges to their regulatory approval or market success, their competitive profile, and, if applicable, their projected sales through 2015.

We were particularly interested in profiling small molecule drugs, therapeutic vaccines and other biologics targeting MS that are in Phase II or III clinical studies or those with unique mechanisms of action in earlier stages of development. We identify the leading MS treatments by formulation, by mechanism of action, and by geographic location. In some cases, we discuss notable compounds that failed in clinical testing, such as Roche and Biogen Idec’s Rituxan (rituximab), or that were pulled from the market due to adverse event or other issues. We also discuss the potential of some compounds that are being tested for other inflammatory or autoimmune disorders that could in the future potentially be tested as a treatment for or used off-label for MS.

Disease-modifying agents to treat MS are currently one of the largest classes of pharmaceutical products by sales in the U.S. and throughout the world. Sales of these agents for MS have grown from less than $1 billion worldwide in 1999 to more than $10 billion in 2009. A period of dynamic growth in the MS disease-modifying product market is expected to continue with seven new agents with unique mechanisms of action or new formulations entering the market between 2010 and the end of 2015. Longer-acting formulations of existing MS products are also expected to have a positive effect on the market as well.

New approaches to treating MS are being pursued by pharmaceutical and biotech companies as many of them look to move beyond agents such as the interferons that primarily slow the progression of MS. These potential new disease-modifying agents with novel mechanisms of action or improved delivery systems will provide powerful new options for patients failing or intolerable to the currently prescribed treatments for MS.

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=152283&rt=Multiple-Sclerosis-MSDrugs-and-Biologics-Technologies-and-Global-Markets.html

Related Reports

Global Multiple Sclerosis Drug Market 2010-2025
http://www.bharatbook.com/detail.asp?id=135347&rt=Global-Multiple-Sclerosis-Drug-Market-2010-2025.html

Multiple Sclerosis Market Forecast
http://www.bharatbook.com/detail.asp?id=130004&rt=Multiple-Sclerosis-Market-Forecast.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook

Author :
Print